Detalhe da pesquisa
1.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecol Oncol
; 168: 157-165, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36442427
2.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol
; 170: 38-45, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36610380
3.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Gynecol Oncol
; 169: 98-105, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36525930
4.
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Gynecol Oncol
; 166(2): 351-357, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641325
5.
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Gynecol Oncol
; 166(1): 117-125, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35599167
6.
Recent advances in fertility preservation.
J Obstet Gynaecol Res
; 45(2): 266-279, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30246274
7.
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mol Cancer Ther
; 22(12): 1404-1412, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676984
8.
Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes.
Cancers (Basel)
; 14(21)2022 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36358604
9.
Techniques for ovarian tissue transplantation and results.
Minerva Ginecol
; 70(4): 424-431, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29644328